🟢 GRAIL is trading 5.7% up in pre-market amid XBI's 3.64% pre-market gain

GRAIL is trading 5.65% higher at $131.72 before the October 21, 2026, open, amid a broad biotech rally.

• XBI is up 3.64% pre-market, alongside positive industry news flow.
• No fresh GRAIL-specific announcement explaining the move was found.
• The FDA advisory committee vote in favor of Galleri approval took place on September 23, not overnight.